Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5DxCD3 Bispecific Antibody: Experience in MonumenTAL-1 : Episode 6

GPRC5D-Related Oral Adverse Events in Multiple Myeloma

December 19, 2023
By Donna Catamero, ANP-BC, OCN, CCRC
Cesar Rodriguez, MD
  • Saad Z. Usmani, MD, MBA, FACP

Opinion
Video

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

      EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

      EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

      EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

      EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

      Now Viewing

      EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

      EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

      EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

      EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

      EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

      This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

      Oral toxicities with talquetamab are nearly universal, with taste changes in 72% of patients, dry mouth in 40%, and dysphagia in 25% arising within the first month but persisting long term. Usmani observes these issues with all talquetamab-treated patients, but they are disproportionately severe in African American patients. Nutrition and supportive measures start early, with schedule modifications offering the best toxicity mitigation after patients respond. Rodriguez notes taste changes in more than 90% of patients, predominantly loss of savoriness although sometimes complete ageusia. Capturing severity is challenged by coarse grading criteria when even grade 1 changes impact quality of life and appetite. The pathophysiologic mechanism, be it taste bud disruption or salivary changes, remains unclear, complicating symptomatic management.

      Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.

      Recent Videos
      “If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
      JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
      Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
      MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
      The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
      JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      Related Content
      Advertisement

      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

      Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

      Tim Cortese
      July 13th 2025
      Article

      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.


      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

      ASCT Shows No Significant MRD Difference vs Isa-KRd in Multiple Myeloma

      Russ Conroy
      July 9th 2025
      Article

      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.


      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.


      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

      Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

      Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

      Related Content
      Multiple Myeloma
      |
      Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5DxCD3 Bispecific Antibody: Experience in MonumenTAL-1
      Advertisement

      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

      Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma

      Tim Cortese
      July 13th 2025
      Article

      A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.


      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

      ASCT Shows No Significant MRD Difference vs Isa-KRd in Multiple Myeloma

      Russ Conroy
      July 9th 2025
      Article

      Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.


      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.


      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

      Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

      Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

      Roman Fabbricatore
      July 2nd 2025
      Article

      Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

      Advertisement
      Advertisement
      Advertisement
      Advertisement
      x
      About
      Advertise
      CureToday.com
      OncLive.com
      OncNursingNews.com
      TargetedOnc.com
      Editorial
      Contact
      Terms and Conditions
      Privacy
      Do Not Sell My Personal Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.